11th February 2020 Editorial by: Paul Carton
Co-Diagnostics CoPrimer™ is Applied to 2019-nCoV Screening Assay
The patented technique CoPrimer™ by Co-Diagnostics, declared by the Journal of Molecular Diagnostics as a 'Technical Advance' due to its 2.5 million improvement in reducing amplification errors has been incorporated into a 2019-nCoV diagnostic kit. The Co-Diagnostics Logix Smart™ 2019-nCoV qPCR test has been made available for research use only (RUO) and is being sold to laboratories, hospitals and institutions.
On the 10th of February Co-Diagnostics announced sales of the patented technology to international markets, just days after its initial launch. The Logix Smart 2019-nCoV is compatible with various manufacturers' PCR devices that are commonly used.
This reduction in amplification errors is based on the CoPrimer's ability to eliminate primer-dimers, a primary cause of mismatching. The test, according to Co-Diagnostics, is "a screening test designed to identify the presence of the novel coronavirus that originated in China before spreading across the world."
Date Published: 11th February 2020
Source article link: http://codiagnostics.com/co-diagnostics-announces-sales-of-new-coronavirus-test/